Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza

Journal of Pharmaceutical Sciences

Volumn 108, Issue 5, 2019, Pages 1896-1904

  Koshimichi, Hiroki ^a   Tsuda, Yoshiyuki ^a   Ishibashi, Toru ^a   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

baloxavir marboxil; cap dependent endonuclease inhibitor; influenza; population pharmacokinetics; S 033188

Indexed keywords

BALOXAVIR MARBOXIL; OSELTAMIVIR; PLACEBO; ANTIVIRUS AGENT; BALOXAVIR; OXAZINE DERIVATIVE; PRODRUG; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ABSORPTION LAG TIME; ADOLESCENT; ADULT; AGED; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG REEXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REDUCTION (CHEMISTRY); SINGLE DRUG DOSE; VIRUS LOAD; VOLUME OF DISTRIBUTION; DRUG EFFECT; METABOLISM; MIDDLE AGED; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; OXAZINES; PRODRUGS; PYRIDINES; THIEPINS; TRIAZINES; VIRUS REPLICATION; YOUNG ADULT;

EID: 85059466941     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2018.12.005     Document Type: Article

References (15)

1. U.S. Food and Drug Administration. Xofluza: package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf, 2018 Accessed: 9th December, 2018.
2. Koshimichi, H., Ishibashi, T., Kawaguchi, N., Sato, C., Kawasaki, A., Wajima, T., Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig 38 (2018), 1189–1196.
3. Fukao, K., Noshi, T., Yamamoto, A., et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J Antimicrob Chemother, 2018, 10.1093/jac/dky462.
4. Bergstrand, M., Hooker, A.C., Wallin, J.E., Karlsson, M.O., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13 (2011), 143–151.
5. Ette, E.I., Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37 (1997), 486–495.
6. Holford, N.H., A size standard for pharmacokinetics. Clin Pharmacokinet 30 (1996), 329–332.
7. Hoffmeyer, S., Burk, O., von Richter, O., et al. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 28 (2000), 3473–3478.
8. Kim, R.B., Leake, B.F., Choo, E.F., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001), 189–199.
9. Sakaeda, T., Nakamura, T., Horinouchi, M., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18 (2001), 1400–1404.
10. Fukami, T., Yokoi, T., The emerging role of human esterases. Drug Metab Pharmacokinet 27 (2012), 466–477.
11. Shimizu, M., Fukami, T., Kobayashi, Y., et al. A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. Drug Metab Dispos 40 (2012), 1183–1190.
12. Chen, Y., Chen, S., Li, X., Wang, X., Zeng, S., Genetic variants of human UGT1A3: functional characterization and frequency distribution in a Chinese Han population. Drug Metab Dispos 34 (2006), 1462–1467.
13. Iwai, M., Maruo, Y., Ito, M., Yamamoto, K., Sato, H., Takeuchi, Y., Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 49 (2004), 123–128.
14. Hyden, F., Sugaya, N., Hirotsu, N., et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379 (2018), 913–923.
15. Watanabe, A., Ishida, T., Hirotsu, N., et al. Baloxavir Marboxil in Japanese Patients with Seasonal Influenza: Dose Response and Virus Type/Subtype Outcomes from a Randomized Phase 2 Study. 2018, Antiviral Research, US in submission.